1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Don't Panic! Novartis Is Still Invested In CAR-T Despite 2Q Silence

Novartis AG's CAR-T cell therapy CTL019, set to be the first in this class to achieve a US FDA filing, might not be an immediate blockbuster owing to its tricky treatment logistics, small initial indication and a lack of physician and patient exposure, but it is still a game changer in immuno-oncology, says Dr. Oz Azam, Novartis's head of cell therapies.

RedBloodCellsOnWhite_1200x675

Novartis AG's cell therapy CTL019, a CAR-T (chimeric antigen receptor T-cells) product, caused a stir last month when the big pharma neglected to include the pipeline-leading therapy on a list of its upcoming potential blockbuster drugs during its second-quarter earnings presentation. But Dr. Oz Azam, global head of cell and gene therapies at Novartis, told Scrip this was not a big deal and indeed there were a number of explanations for the medicine's exclusion.

While Azam said he couldn’t comment directly on why Novartis's senior management team did not include CTL019 on a slide...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

PureTech’s New Spin-Off Wants Partners For Pulmonary Fibrosis Drug

 
• By Andrew McConaghie

Deupirfenidone hit its Phase II endpoint but the program remains risky and PureTech’s new Celea Therapeutics will aim to pull in extra funding for its late-stage development.

Xenon Nears Phase III Readout For Potential Epilepsy And Depression Blockbuster

 
• By Andrew McConaghie

Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 
• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.